tbuckley/cabot-search huggingface dataset:
BENIGN GASTRIC POLYPS
Authors: D NIEMETZ, G K WHARTON
Journal: Annals of Internal Medicine (1955)

Article1 February 1955BENIGN GASTRIC POLYPSDAVID NIEMETZ, M.D., F.A.C.P., GEORGE K. WHARTON, M.D., F.A.C.P.DAVID NIEMETZ, M.D., F.A.C.P.Search for more papers by this author, GEORGE K. WHARTON, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-42-2-339 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBenign polyps of the stomach were discovered in 32 patients at the Los Angeles County Hospital between 1943 and 1953, approximately a 10 year period. These polyps were both sessile and pedunculated, single and multiple, and those studied histologically were all adenomatous.Table 1 shows age-sex distribution. There was no appreciable sex difference. The majority were found in patients in their seventh and eighth decades. Incidentally, the racial distribution corresponded to that of the hospital population as a whole, approximately 2:1, Caucasian to Negro.The diagnostic procedures are noted in table 2. Twenty-three patients had upper gastrointestinal series, and in...Bibliography1. HardtSteigmannMilles LLFG: Gastric polyps, Gastroenterology 11: 629, 1948. MedlineGoogle Scholar2. ThompsonOyster HLJM: Neoplasms of the stomach, Gastroenterology 15: 185, 1950. CrossrefMedlineGoogle Scholar3. WheelockAtkinsonJennings MCAJR: Gastric polyposis, Gastroenterology 18: 135, 1951. CrossrefMedlineGoogle Scholar4. CareyHay JBLJ: Gastric polyps, Gastroenterology 14: 280, 1950. CrossrefMedlineGoogle Scholar5. EdwardsBrown RVCH: Benign gastric polyps and their relation to carcinoma of the stomach, Gastroenterology 16: 531, 1950. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication March 30, 1954.From the Department of Medicine, University of Southern California School of Medicine, and Los Angeles County Hospital, Los Angeles, California.Presented at the Southern California Regional Meeting of the American College of Physicians at Riverside, California, February 14, 1954. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPrecancerous lesions of the stomachMalignant potential of gastric polypsGutartige Geschwülste des MagensHistogenetical Study of Gastric Carcinomas in the Japanese. Analysis of 150 Cases Treated in Relatively Early StagesGastric polypsGastric polypsGastric polyps.A histogenetic classification and its relation to carcinomaAdenomatous polyps of the stomach.A clinical and pathological study of 153 casesPrecancerous disease of the gastrointestinal tract 1 February 1955Volume 42, Issue 2Page: 339-344KeywordsHospital medicineStatistical distributionsStomach ePublished: 1 December 2008 Issue Published: 1 February 1955 PDF downloadLoading ...
Method for the Quantitative Morphologic Analysis of Tissues
Authors: Chalkley, H. W.
Journal: JNCI Journal of the National Cancer Institute (1943)

Journal Article Method for the Quantitative Morphologic Analysis of Tissues Get access H. W. Chalkley H. W. Chalkley senior physiologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 1, August 1943, Pages 47–53, https://doi.org/10.1093/jnci/4.1.47 Published: 01 August 1943
Temporal trends in first-line chemotherapy treatment among elderly stage IIIB/IV non-small cell lung cancer (NSCLC) patients in the United States: Evidence from SEER-Medicare data
Authors: K. Lang, M. D. Marciniak, D. Faries, M. Stokes, D. Buesching, C. Earle, J. Treat, D. Thompson
Journal: Journal of Clinical Oncology (2007)

17002 Background: Data regarding first-line chemotherapy treatment among advanced-staged NSCLC patients is lacking. The purpose of this analysis was to assess first-line treatment patterns over time among elderly patients with Stage IIIB/IV NSCLC. Methods: Patients aged 65 years and older diagnosed with Stage IIIB/IV NSCLC between 1997 and 2002 were identified and followed over time using the SEER-Medicare database to evaluate temporal trends in first-line chemotherapy treatment. Results: Chemotherapy use increased from approximately 28% of Stage IIIB/IV patients diagnosed in 1997 to 36% of patients diagnosed in 2002. Among identifiable first-line treatments, cisplatin or carboplatin and taxane (C/CT) doublet therapy was the most common treatment in all years (approximately 50% or greater). The use of single-agent taxanes and gemcitabine increased over time (taxane use increased from 3.3% in 1997 to 7.6% in 2002; gemcitabine use increased from 0.6% in 1997 to 5.1% in 2002), while use of single agent cisplatin or carboplatin (C/C) declined (from 10.0% in 1997 to 3.1% in 2002). Use of doublet therapy with C/C and either a taxane or gemcitabine also increased over time (with the largest increase for the gemcitabine combination from 0.3% in 1997 to 11.8% in 2002). Correspondingly, use of doublet C/C and any other therapy declined markedly (from 18.9% in 1997 to 3.7% in 2002). Use of 3 or more agents as first-line treatment was infrequent across study years (&lt;1.0%). Treatment discontinuation was substantial (&gt;60% for all regimens). Conclusions: Our findings indicate relatively low but increasing use of first-line chemotherapy treatment among elderly Stage IIIB/IV NSCLC patients. [Table: see text]
Modified Sequential Therapy Containing Levofloxacin Versus Levofloxacin Triple Therapy in the Second Line Treatment of Helicobacter pylori: A Randomized Trial
Authors: Jyh-ming Liou, Ming-Shiang Wu, C.C. Chen, C.Y. Chang, Y.J. Fang, J.T. Lin
Journal: Clinical Gastroenterology and Hepatology (2015)
Synaptic adhesion molecule IgSF11 regulates synaptic transmission and plasticity
Authors: Seil Jang, Daeyoung Oh, Yeunkum Lee, Eric Hosy, Hyewon Shin, Christoph van Riesen, Daniel Whitcomb, Julia M Warburton, Jihoon Jo, Doyoun Kim, Sun Gyun Kim, Seung Min Um, Seok-kyu Kwon, Myoung-Hwan Kim, Junyeop Daniel Roh, Jooyeon Woo, Heejung Jun, Dongmin Lee, Won Mah, Hyun Kim, Bong-Kiun Kaang, Kwangwook Cho, Jeong-Seop Rhee, Daniel Choquet, Eunjoon Kim
Journal: Nature Neuroscience (2015)
Gemcitabine/5-FU/leucovorin for the treatment of pancreatic cancer
Authors: R. Malayeri, M. Ghassem Boland, A. R. Maadi
Journal: Journal of Clinical Oncology (2008)

15651 Background: Until now, there is no standard chemotherapy protocol for pancreatic cancer. As this disease is very hard to treat and most studies have shown low response rates and survival, we thought the best treatment should show some efficacy, be easy to administer and have the least negative impact on the quality of life of these patients. Methods: Starting from 11/2003, 53 chemo- naïve patients, 37 male, 16 female, age 35–73, median: 54, with different stages of pancreatic cancer were treated with a chemotherapy protocol consisting of Gemcitabine 1250 mg/m2 on day 1, 5-FU 450 mg/m2 and Leucovorin 100 mg/m2 on days 1–3. Patients had a CT scan at the beginning and after every 4 cycles. The treatment was repeated every 2 weeks and patients who responded or had a stable disease were treated up to a maximum of 8 cycles. The clinical trial is still ongoing. Results: Sixteen of our patients received this protocol as their adjuvant chemotherapy after an R0 operation. 11 patients had a locally advanced disease and 26 patients had metastasized at time of diagnosis, mostly to the liver. Two patients died before receiving 4 cyces of treatment due to progression of their disease. 14 patients,who showed a progression in their CT scan after 4 cycles, had to discontinue treatment, the total number of 8 was received by the other 23 patients. Toxicity data are available for all 53 patients and no grade III-IV treatment related toxicity was seen in the whole population. Evaluation of response and survival: All patients, who received this protocol as an adjuvant treatment are alive after a median follow-up of 65 months. In our patients with stage III or IV a partial remission and a stable disease were seen in 19 and 40% of the patients, respectively. The patients received no second-line treatment and the median progression free and median overall survival were 5.5 and 7.5 months, respectively. A median duration of response of 8.5 months was seen in the patients who primarily responded to chemotherapy. Conclusions: In conclusion the chemotherapy protocol was easy to administer in an outpatient setting, had a very preferable toxicity profile and showed good efficacy in this patient population. This chemotherapy protocol warrants further investigation, also in combination with targeted therapies such as erlotinib or bevacizumab. No significant financial relationships to disclose.
TRPC6 is the endothelial calcium channel that regulates leukocyte transendothelial migration during the inflammatory response
Authors: Evan W. Weber, Fei Han, Mohammad Tauseef, Lutz Birnbaumer, Dolly Mehta, William A. Muller
Journal: The Journal of Experimental Medicine (2015)

Leukocyte transendothelial migration (TEM) is a tightly regulated, multistep process that is critical to the inflammatory response. A transient increase in endothelial cytosolic free calcium ion concentration (↑[Ca2+]i) is required for TEM. However, the mechanism by which endothelial ↑[Ca2+]i regulates TEM and the channels mediating this ↑[Ca2+]i are unknown. Buffering ↑[Ca2+]i in endothelial cells does not affect leukocyte adhesion or locomotion but selectively blocks TEM, suggesting a role for ↑[Ca2+]i specifically for this step. Transient receptor potential canonical 6 (TRPC6), a Ca2+ channel expressed in endothelial cells, colocalizes with platelet/endothelial cell adhesion molecule-1 (PECAM) to surround leukocytes during TEM and clusters when endothelial PECAM is engaged. Expression of dominant-negative TRPC6 or shRNA knockdown in endothelial cells arrests neutrophils apically over the junction, similar to when PECAM is blocked. Selectively activating endothelial TRPC6 rescues TEM during an ongoing PECAM blockade, indicating that TRPC6 functions downstream of PECAM. Furthermore, endothelial TRPC6 is required for trafficking of lateral border recycling compartment membrane, which facilitates TEM. Finally, mice lacking TRPC6 in the nonmyeloid compartment (i.e., endothelium) exhibit a profound defect in neutrophil TEM with no effect on leukocyte trafficking. Our findings identify endothelial TRPC6 as the calcium channel mediating the ↑[Ca2+]i required for TEM at a step downstream of PECAM homophilic interactions.
Abstract P325: Association of Risk Factors and Extra-coronary Atherosclerosis with Progression of Coronary Artery Calcification in the Framingham Heart Study
Authors: Oyere K Onuma, Karol M Pencina, Joseph M Massaro, Udo Hoffman, Christopher J O'Donnell
Journal: Circulation (2014)

Background: Progression of coronary artery calcification (CAC) is associated with future incidence of adverse cardiovascular disease. However, the interplay of CAC progression and atherosclerosis in different vascular beds has been less studied. We tested for the association of risk factors and baseline abdominal aortic calcification (AAC) with CAC progression in a large community cohort. Methods: We determined risk factors, baseline AAC/CAC, and CAC progression in a sample of 1994 asymptomatic white participants from the Framingham Heart Study (FHS) who had undergone serial CT scanning within an average of 6.1 years. The primary outcomes were: (a) incident calcification (CAC &gt; 0) in participants free of CAC at baseline; and (b) absolute progression of CAC (CAC follow-up &gt; CAC baseline) in participants with detectable baseline CAC. To test the effect of risk factors and baseline AAC/CAC on CAC progression, we employed multivariable stepwise logistic and linear regression models of CAC progression with/without AAC, adjusted for traditional CVD risk factors. Results: There were 1118 participants free of CAC at the baseline scan, of which 18.8% developed CAC in the follow-up scan. Of the 776 participants with detectable CAC at baseline, 84.9% developed progression of baseline CAC. In both subsets, AAC was a highly significant predictor of CAC incidence or progression, independent of other risk factors. Of note, the stepwise model including baseline AAC as a candidate for entry resulted in the same set of non-AAC predictors of CAC incidence or progression as the model without AAC. Table 1 displays the final logistic regression results for the cohort free of CAC. The AUC improved to 0.738 compared to an AUC of 0.722 for the model without AAC (p=0.002). Conclusion: AAC is a strong independent predictor of CAC progression determined by incident CAC and CAC progression. Addition of AAC to the model that predicts incident CAC improves discrimination in a cohort free of baseline CAC.
A multi-gene algorithm as predictor of response to chemo-radiotherapy in head and neck cancer
Authors: M. Gasco, N. Syed, P. Smith, G. Numico, I. Colantonio, O. Garrone, C. Granetto, G. Di Costanzo, M. Merlano, T. Crook
Journal: Journal of Clinical Oncology (2006)

10086 Background: Chemo-radiotherapy results in clinical cure for stage III/IV head and neck cancer in approximately 40% of cases, with significant treatment-associated morbidity and mortality. Molecular genetic factors predictive of treatment outcome would clearly be of value in selection of patients with highest probability of response. We have analysed the structure and epigenetic regulation of specific genes as possible predictors of outcome to chemo-radiotherapy. The genes analyzed were: p53 (single nucleotide polymorphism (SNP) and mutation), MDM2 (SNP), Chfr (methylation), CRABP1 (methylation). Methods: 84 patients with locally advanced head and neck cancer receiving cisplatin-based chemo-radiotherapy were studied. SNP genotypes were determined by direct sequencing of DNA from normal tissue. Acquired mutations in p53 and aberrant methylation in the CpG islands of specific genes were analyzed by direct sequencing and methylation-specific PCR. Results: There were 6 treatment-related deaths in 84 patients, all occurring in cases with germ-line haplotype p53 72 Arg/Arg, MDM2 309T/T. At the time of analysis, 39/84 (46%) patients had progressed or died, with median time to progression or death = 17.3 months. Complete response was more common in patients whose genetic/epigenetic profile was p53 72 Arg/Arg wild type, MDM2 309 G/G, Chfr methylated, CRABP1 methylated, compared to the profile p53 72 Arg/Arg mutant, MDM2 309 T/T, Chfr unmethylated, CRABP1 unmethylated (91% vs 46%, log rank p = 0.002). Progression-free survival was significantly longer for patients with the profile p53 72 Arg/Arg wild type, MDM2 309 G/G, Chfr methylated, CRABP1 methylated, compared to those with p53 72 Arg/Arg mutant, MDM2 309 T/T, Chfr unmethylated, CRABP1 unmethylated (% surviving progression-free at 2 years = 74% vs 36%, p = 0.001). Overall survival was significantly longer in patients with the profile p53 72 Arg/Arg wild type, MDM2 309 G/G, Chfr methylated, CRABP1 methylated compared to those with p53 72 Arg/Arg mutant, MDM2 309 T/T, Chfr unmethylated, CRABP1 unmethylated (% surviving at 2 years = 88% vs 40%, p = 0.0004). Conclusions: Genetic and epigenetic parameters influence the toxicity and clinical outcome of chemo-radiotherapy in head and neck cancer. No significant financial relationships to disclose.
CEX (celecoxib, oxaliplatin, capecitabine) and XRT: A novel neoadjuvant approach for locally advanced rectal cancer
Authors: W. M. Adler, B. Liem, G. Heywood, G. Wong, F.-C. Lee
Journal: Journal of Clinical Oncology (2005)

3744 Background: Concurrent neoadjuvant chemoradiation in operable rectal cancer seeks to: decrease tumor burden; increase chance for sphincter-sparing surgery; and demonstrate tumor response to selected chemotherapy. Overall survival impact is debatable, but data support a decreased incidence of local recurrence. 5-FU is the standard radiosensitizing agent for rectal cancer treatment. Alone, 5-FU may not eliminate micrometastatic disease. Preoperative chemotherapy should include drugs that eliminate micrometastatic disease, provide good radiosensitization and limit side effects. We retrospectively report our experience with celecoxib, oxaliplatin, and capecitabine (CEX) with concurrent radiation for advanced, operable rectal cancer. Methods: From March ’03, to December ’04, ten patients underwent treatment. Age range is 38 to 66; three are women. Pre-treatment staging included colonoscopy, endoscopic rectal ultrasound, and CT. Seven patients had 3B or 3C disease; three patients had 2A or 2B disease. Nine patients demonstrated lymph node involvement. 5 ½-week radiation dose was 5040 cGy. Concomitant chemotherapy was: celecoxib 200 mg bid daily; oxaliplatin 50 mg/m2 weekly; and capecitabine 1500 mg/m2/d Mondays-Fridays. Results: Nine patients had surgery; one awaits surgery. One patient never received oxaliplatin. There were no pathologic remissions. Seven patients had downstaging of their disease: five went from N1 or N2 to N0; five lesions went from T4 or T3 to T3 or T2. Two patients went from Stage 3 to Stage I. Side effects were tolerable. There were no significant dose reductions and no treatment delays due to neutropenia or neuropathy. Grade 1/2 anemia was the primary hematologic side effect. One patient discontinued capecitabine due to pruritic rash. Two patients had grade 4 diarrhea with dehydration. These two patients did not take celecoxib as instructed. One, after taking celecoxib as intended, had no problems. All patients are alive. None has definitive evidence of recurrence. Conclusions: This regimen is well-tolerated and active. A prospective phase II trial is underway. No significant financial relationships to disclose.
Improving the Nephrology Match
Authors: Chi-yuan Hsu, Mark G. Parker, Michael J. Ross, Rebecca J. Schmidt, Raymond C. Harris
Journal: Journal of the American Society of Nephrology (2015)

The Fellowship Match process was designed to provide applicants and program directors with an opportunity to consider all their options before making decisions about post-residency training. In a Match, applicants can choose the programs that best suit their career goals, and program directors can consider all candidates before preparing a rank order list. The Match is a contract, requiring obligations of both programs and applicants to achieve success, ensure uniformity, and standardize participation.
Ionizing radiation modifies immune-related molecular profiles of tumor-derived exosomes
Authors: Julie M Diamond, Jessica R Chapman, Beatrix Ueberheide, Silvia Formenti, Sandra Demaria
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Exosomes are microvesicles (30-100nm) released from living cells that shuttle and transfer selected cellular biomolecules, including cytokines, cell surface molecules, growth factors, mRNA, and miRNA. Tumor-derived exosomes (TEX) allow for a sophisticated means of communication
Use of a self-assessment questionnaire for food safety education in the home kitchen - Los Angeles County, California, 2006-2008.
Authors: T. Kuo, H. dela Cruz, M. Redelings, L. V. Smith, R. Reporter, P. A. Simon, J. E. Fielding, S. M. Teutsch
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
The dose–response effect of physical activity on cancer mortality: findings from 71 prospective cohort studies
Authors: Tingting Li, Shaozhong Wei, Yun Shi, Shuo Pang, Qin Qin, Jieyun Yin, Yunte Deng, Qiongrong Chen, Sheng Wei, Shaofa Nie, Li Liu
Journal: British Journal of Sports Medicine (2015)

The WHO recommends moderate physical activity to combat the increasing risk of death from chronic diseases. We conducted a meta-analysis to assess the association between physical activity and cancer mortality and the WHO recommendations to reduce the latter.MEDLINE and EMBASE were searched up until May 2014 for cohort studies examining physical activity and cancer mortality in the general population and cancer survivors. Combined HRs were estimated using fixed-effect or random-effect meta-analysis of binary analysis. Associated HRs with defined increments and recommended levels of recreational physical activity were estimated by two-stage random-effects dose-response meta-analysis.A total of 71 cohort studies met the inclusion criteria and were analysed. Binary analyses determined that individuals who participated in the most physical activity had an HR of 0.83 (95% CI 0.79 to 0.87) and 0.78 (95% CI 0.74 to 0.84) for cancer mortality in the general population and among cancer survivors, respectively. There was an inverse non-linear dose-response between the effects of physical activity and cancer mortality. In the general population, a minimum of 2.5 h/week of moderate-intensity activity led to a significant 13% reduction in cancer mortality. Cancer survivors who completed 15 metabolic equivalents of task (MET)-h/week of physical activity had a 27% lower risk of cancer mortality. A greater protective effect occurred in cancer survivors undertaking physical activity postdiagnosis versus prediagnosis, where 15 MET-h/week decreased the risk by 35% and 21%, respectively.Our meta-analysis supports that current physical activity recommendations from WHO reduce cancer mortality in both the general population and cancer survivors. We infer that physical activity after a cancer diagnosis may result in significant protection among cancer survivors.
O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study
Authors: X. Forns, M. Berenguer, K. Herzer, M. Sterneck, M.F. Donato, P. Andreone, S. Fagiuoli, T. Cieciura, M. Durlik, J.L. Calleja, Z. Marino, A. Simion, U. Shukla, T. Verbinnen, O. Lenz, S. Ouwerkerk-Mahadevan, M. Peeters, R. Kalmeijer, J. Witek
Journal: Journal of Hepatology (2015)